ArticleCureus2025
A Rare Case of Thymic Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic mucosa-associated lymphoid tissue (MALT) lymphoma is a type of diffuse B-cell lymphoma located in the thymus that is extremely rare. This case report illustrates the treatment of a 39-year-old Asian female patient with thymic MALT lymphoma. She presented with constitutional symptoms and chest pain. A CT scan of the chest revealed a soft tissue density in the right anterior mediastinum measuring 4×4.2 cm, likely originating from the thymus. After counseling between the options of surveillance imaging, CT-guided biopsy, or upfront surgery, the patient opted for surgical resection of the mass for both diagnostic and therapeutic intent. She then underwent robot-assisted excision of the mediastinal mass and total thymectomy on July 6, 2023. Intraoperative findings noted a 3 cm thymic mass without direct invasion into other local structures. The histological report revealed extranodal marginal zone lymphoma of MALT type. The patient was then referred to medical oncology, where it was determined that surgical resection of the tumor in her case was sufficient for oncological treatment, and no further radiotherapy or chemotherapy was required. The patient was also screened for possible autoimmune conditions and was found to be ANA positive, as thymic MALT lymphoma has known autoimmune associations with Sjögren's disease and SLE, among others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.